Penehyclidine for Prevention of Nausea and Vomiting After Bimaxillary Surgery

• Status: Completed
• Trial end date: 2021-04-15
• Target enrollment: 0
• Participant gender: All

Summary

Postoperative nausea and vomiting (PONV) is a common complication after surgery. Patients undergoing orthognathic surgery are reported to have a high rate of PONV, especially those undergoing bimaxillary surgery. Activation of cholinergic system plays an important role in the development of PONV. Penehyclidine is an muscarinic antagonists which selectively block M1 and M3 receptors and is commonly used to decrease oral secretion. The investigators hypothesize that continuously administrated penehyclidine during perioperative period can reduce the incidence of PONV in patients undergoing bimaxillary surgery.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Peking University First Hospital
• Collaborator: Peking University Hospital of Stomatology

Criteria

Inclusion Criteria:

1. Age ≥18 years but <60 years; body mass index ≥18 but <30 kg/m2;

2. Scheduled to undergo elective bimaxillary surgery under general anesthesia;

3. Planned to use patient-controlled intravenous analgesia (PCIA) after surgery;

4. Provide written informed consents.

Exclusion Criteria:

1. Presence of glaucoma;

2. Allergic to penehyclidine, atropine, scopolamine or other anticholinergic drugs;

3. Acute or chronic nausea and/or vomiting, or gastrointestinal motility disorders before surgery;

4. Preoperative antiemetic therapy within 12 hours;

5. History of schizophrenia, Parkinson's disease or profound dementia, or language barrier;

6. Severe hepatic dysfunction (Child-Pugh class C), severe renal dysfunction (requirement of renal replacement therapy before surgery) or American Society of Anesthesiologists physical status ≥IV.